Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

Abstract

Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody-drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia.Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively.Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively.Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.

Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability

“…Moreover, several studies have reported prolonged disease control among responding patients [ 83 , 84 ]. Results consistent with those from clinical trials have also been reported from the Czech Republic and Slovakia, where 58 patients had overall and CR rates of 47% and 33%, respectively, and 1-year, 2-year and 3-year OS rates from initiation of BV of 78%, 62%, and 41%, respectively [ 85 ]. Specifically in elderly patients or transplant-ineligible patients, real-life studies have also confirmed the effectiveness of BV, with response rates of 68% to 74% [ 84 , 86 ].…”

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19

“… 10 Progression-free survival (PFS) rates of BV in 1 and 2 years were reported 63.2% and 45.2%, respectively, with the median PFS of 1.38 years. 11 …”

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

“…Although there was a paucity of data on the real-world use of brentuximab vedotin as consolidation therapy post-ASCT for some time, several recent retrospective studies have assessed the effectiveness of this approach in adults, children, and adolescents, and support the results of the AETHERA trial [ 50 – 54 ]. Real-world data also support the efficacy and acceptable safety profile of brentuximab vedotin in adults with refractory or relapsed cHL [ 55 , 56 ], including as a bridge to ASCT [ 57 ], and the use of brentuximab vedotin in combination with bendamustine in children, adolescents, and adults with cHL [ 58 , 59 ].…”

“…Real-world data also support the efficacy and acceptable safety profile of brentuximab vedotin in adults with refractory or relapsed cHL [ 55 , 56 ], including as a bridge to ASCT [ 57 ], and the use of brentuximab vedotin in combination with bendamustine in children, adolescents, and adults with cHL [ 58 , 59 ].…”